The CBO report estimated that 2% of the 12.5 million Medicare beneficiaries would take the drug, resulting in a total direct cost of somewhere between $750 million per year, if all recipients took Wegovy, and $1 billion if all recipients took the slightly more expensive Zepbound
Musculoskeletal co-morbidities in patients with transthyretin amyloid cardiomyopathy: a systematic review
For pets with chronic conditions, the positive response to treatment, as evidenced by the pet owners perceived benefits analyzed in Section 4.6, suggests that demonstrable improvements to a pets QoL are more likely to encourage treatment adherence
Kotani H, Terada M, Mori M, Horisawa N, Sugino K, Kataoka A,
Some GLP-1 receptor agonists have demonstrated cardiovascular benefits in specific patient populations, though this varies by individual agent